Breast cancer is one of the most significant health issues in the world, and resistance to treatment and a lack of targets that can be addressed with drugs limit the effectiveness of the existing treatment options. The development of proteolysis-targeting chimeras (PROTACs) has shifted the concept of occupancy-based in...
Hannah Lalengzuali Fanai, B. Babu, K. Rajagopal et al.· Molecular Biology Reports· 0 citations
The identification of new molecular targets and the growth of personalized therapies for cancer depend on current studies, and it is believed that new advances in molecular science will contribute to the development of innovative and successful methods for therapy, and eventually decrease the prevalence of malignancies...
Hardha Balachandran, Gowramma Byran, S. Murugesan et al.· Current Cancer Drug Targets· 0 citations
The docking, ADMET, and MD simulation studies indicate that the designed shikimic acid derivatives have good binding affinity and drug-like properties, and are stable in the active site of the SARS-CoV-2 main protease.
Hardha Balachandran, Kaviarasan Lakshmanan, Dipen Purohit et al.· Current Computer - Aided Dru...· 0 citations
Overall, compound B2 emerged as a promising PARP1 inhibitor with strong binding affinity, structural stability, and significant in vitro anticancer activity, warranting further optimization and preclinical investigation.
Hardha Balachandran, Subhajit Majumder, Gowramma Byran et al.· Current Medicinal Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
